Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Prediction of Chronic Disease Using Explainable Hybrid Machine Learning

NCT07845084 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-08-30
Last updated
2026-09-28

Condition(s) studied

Physical ActivitiesMachine Learning

Study summary

In this study, a 28-item questionnaire developed by the researchers (Aysun Atacan and Gülşen Taşkın) will be used as the data collection tool. Since the intellectual property rights and developer identity belong to the researchers, there are no copyright or usage restrictions. Containing both qualitative and quantitative evaluation questions, the questionnaire consists of 5 main sections: personal information, daily life assessment, walking level assessment, household chores assessment, and work/workplace assessment. Eight of the questions cover sociodemographic information, while 20 focus on determining and evaluating physical activity levels in daily life, walking, home, work, and transportation. Participants are asked to answer the questions by considering their lifestyle over the past month. Based on these data-recorded according to how many days per week and how many minutes per day the activities are performed-calculations will be made by multiplying the MET value, frequency (days/week), and duration (minutes/day) to obtain the "MET-min/week" score. Participants will be categorized into three groups based on their total weekly MET expenditures: \<600 MET-min/week as inactive, 600-3000 MET-min/week as minimally active, and \>3000 MET-min/week as health-enhancing physically active (sufficiently active); and into groups based on their average daily step counts: \<5000 as sedentary/inactive, 5001-7499 as low active, 7500-9999 as somewhat active, 10000-12499 as active, and \>12500 as highly active. Chronic disease risk predictions will then be evaluated via machine learning based on these physical activity levels and step counts.

The primary aim of this research is to quantitatively demonstrate the impact of physical activity levels and lifestyle habits on chronic disease risk factors using machine learning (ML) methods. The models to be developed aim not only for high predictive performance but also for the clinical interpretation of which physical activity parameters are more decisive on disease risk, utilizing explainable artificial intelligence methods such as SHapley Additive exPlanations (SHAP). Consequently, the goal is to establish a decision support mechanism for the early detection of individuals at risk and to place personalized exercise prescriptions on a scientific foundation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Being aged between 18 and 64 * Participating in the study voluntarily Exclusion Criteria: * Not being aged between 18 and 64 Not agreeing to participate in the study

Primary outcome measure(s)

  • hypothesis — Baseline
    Estimation of the presence of chronic disease within an 85-95% confidence interval, based on physical activity and demographic data.

Trial sites (1)

FacilityCityRegionStatus
Afyonkarahisar Health Sciences University Afyonkarahisar Merkez
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07845084 on ClinicalTrials.gov ↗ ← All trials in Turkey